Seller record · Telehealth service

Longevixx

Fails 2 of 8 criteria. S3, pharmacy identification: The site names no filling pharmacy. The product pages and the terms refer only to licensed U.S. compounding pharmacies and a partner compounding pharmacy. 1 more criterion also fails; see the table below.

At a glance

LongevixxTelehealth service

6/8criteria passed
Price
Semaglutide from $139 a month, tirzepatide from $149
Sells
semaglutide injection, tirzepatide injection, GLP-1 microdose, and 5 more
FDA letters
None on file
Visit LongevixxSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling semaglutide and tirzepatide injections, a GLP-1 microdose and an oral GLP-1, alongside tesamorelin, sermorelin, NAD+ and PT-141, with a starting monthly price for each. It names no filling pharmacy and prints a Charlotte, North Carolina address.

Operating entity Longevixx LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSLongevixx's peptides page; Longevixx's terms
S2Prescription gatingPASSLongevixx's eligibility page; Longevixx's website
S3Pharmacy identificationFAILLongevixx's semaglutide product page; Longevixx's terms
S4Compounding disclosurePASSLongevixx's peptides page; Longevixx's tesamorelin product page
S5Analytical documentationFAILLongevixx's peptides page; Longevixx's terms
S6Business addressPASSLongevixx's contact page; Longevixx's terms; Longevixx's privacy page
S7Price disclosurePASSLongevixx's peptides page; Longevixx's website
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews every order and prescribes only when clinically appropriate, and the terms say no prescription product is available without a consultation in which a provider finds it appropriate.Source: Longevixx's peptides page; Longevixx's terms.
S2PASSThe eligibility button opens an assessment whose first screen asks what the buyer would like support with, and the site says no charge is made unless a provider approves.Source: Longevixx's eligibility page; Longevixx's website.
S3FAILThe site names no filling pharmacy. The product pages and the terms refer only to licensed U.S. compounding pharmacies and a partner compounding pharmacy.Source: Longevixx's semaglutide product page; Longevixx's terms.
S4PASSCompounded medications are not FDA-approved, printed in the disclaimer at the foot of every page and beneath the price list on the peptides page.Source: Longevixx's peptides page; Longevixx's tesamorelin product page.
S5FAILNo certificate of analysis or lot document is published on the product pages, the terms, the privacy policy or the HIPAA notice.Source: Longevixx's peptides page; Longevixx's terms.
S6PASSLongevixx LLC at 4111 E Rose Lake Drive #9969, Charlotte, NC 28217, printed as the clinic address on the contact page. The terms, the privacy policy and the HIPAA notice give only an email address.Source: Longevixx's contact page; Longevixx's terms; Longevixx's privacy page.
S7PASSThe semaglutide injection from $139 a month, the tirzepatide injection from $149, the GLP-1 microdose from $129 and the oral GLP-1 from $229 a month. Tesamorelin from $299, sermorelin and PT-141 from $249 and NAD+ from $199 a month. The home page banner gives GLP-1 weight loss from $149 a month, and its eligibility tool gives plans from $129 a month.Source: Longevixx's peptides page; Longevixx's website.
S8PASSNo FDA warning letter names Longevixx or Longevixx LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide injection, tirzepatide injection, GLP-1 microdose, GLP-1 oral, tesamorelin, sermorelin, NAD+, PT-141.

Visit Longevixx

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.